Clinical trial
An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis
NCT01445769 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Assessment of an Alternative Dosing Strategy of Ruxolitinib in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and Post-essential Thrombocythemia Myelofibrosis
- Lead sponsor
- Incyte Corporation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2011
- Completion date
- April 30, 2013
- Enrollment
- 45 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.
post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis, primary myelofibrosis